AI-Generated Summary

This article argues that India's biotech sector, despite its talent and patient base, is hampered by outdated regulations and a culture that prioritizes volume over discovery, risking its leadership in the AI-driven future of medicine. It advocates for sweeping regulatory reforms, including AI-enabled reviews and adaptive trial designs, alongside cultural shifts to reward research and build credibility. Implementing these changes is crucial for India to seize the opportunity to become a global biotech leader and achieve its ambitious bio-economy goals.

In a nutshell

The piece offers a critical analysis of the systemic barriers preventing a major market like India from fully leveraging AI in drug discovery and biotech, highlighting the urgent need for policy-level intervention and cultural transformation. Its insights are relevant for understanding global market dynamics and the challenges of fostering innovation in regulated industries.

Source: Hindustan Times